Dose Escalation Study MORAb-066 Targeting TF-expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Pancreatic Cancer|Colorectal Cancer|Non-small-cell Lung Cancer|NSCLC|Adenocarcinoma
Interventions: DRUG: MORAb-066
Sponsor: Morphotek
Collaborators: SCRI Development Innovations, LLC